Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters.
Abstract: The most prevalent TDR drug resistance mutations, in both LP and NLP, were K103N/S, T215rev, T215FY, M184I/V, M41I/L, M46I/L, and L90M.
Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
PMID: 34741609
2022
The Journal of antimicrobial chemotherapy
Result: Sixteen participants had all of the TAM 1 pathway mutations (M41L, L210W and T215Y), 11 had all of the TAM 2 pathway mutations (D67N, K70R, T215F and K219Q/E) and four had the mutations for both pathways.
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
PMID: 34694878
2022
Antimicrobial agents and chemotherapy
Result: Three participants had additional treatment-emergent resistance-associated reverse transcriptase substitutions of T215F/L, T215F/I/S/T and M230I/M, or M184V (n = 1 each) at PDVF.
Table: T215F/L
Table: T215F
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Table: T215F/Y
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.
PMID: 34327247
2021
Open forum infectious diseases
Method: The variables expressing NRTI RAMs were identified as follows: (1) presence versus absence of any NRTI RAM; (2) presence versus absence of at least 1 TAM (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E); (3) presence versus absence of M184V/I (with or without other RAMs); (4) presence versus absence of M184V/I not associated with TAMs; (5) presence versus absence of M184V/I combined with at least 1 TAM.
High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.
Result: The most frequently detected DRMs were M184I/V (68/82; 82.9%), K70E/R (16/82; 19.5%), and T215F/Y (17/82; 20.7%) to NRTI and K103N/S (51/82; 62.1%), P225H (15/82; 18.2%), and V106A/I/M (11/82; 13.4%) to NNRTI (Figure 1).
Result: Thymidine analog mutations (TAM) were detected in 35.4% of the individuals [17.1% (14/82) TAM-1 (including M41L, L210W, and T215Y) and 20.7% (17/82) TAM-2 (including D67N, K70R, T215F, and K219Q/E
Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
Discussion: It is no surprise that NNRTI-related mutations increased rapidly in China recently, and M184V/I and T215I/Y/S/D/F were the main NRTI DRMs in ART-naive and ART-treated individuals, respectively.
Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.
Discussion: In consistent with this study, quite a number of global and regional genetic analyses of HIV-1 have unanimously reported that the most globally prevalent NRTI resistance mutations is M184V followed by thymidine analog-associated mutations (TAM) including M41L, D67N, K70R, L210W, T215Y/F and K219Q/E, and, the most prevalent NNRTI was K103N.
Determination of reverse transcriptase inhibitor resistance mutations in HIV-1 infected children in Cote d'Ivoire.
HIV mutation literature information.
PMID: 
2022
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT